EAM
RMD icon

Eukles Asset Management’s ResMed RMD Stock Holding History

Eukles Asset Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.36M Sell
19,413
-3,323
-15% -$828K 1.94% 14
2025
Q4 		$5.48M Sell
22,736
-129
-0.6% -$33K 2.13% 11
2025
Q3 		$6.26M Sell
22,865
-73
-0.3% -$19.9K 2.44% 9
2025
Q2 		$5.92M Buy
22,938
+43
+0.2% +$10.3K 2.42% 8
2025
Q1 		$5.13M Buy
22,895
+562
+3% +$131K 2.25% 10
2024
Q4 		$5.11M Sell
22,333
-933
-4% -$225K 2.18% 10
2024
Q3 		$5.68M Sell
23,266
-89
-0.4% -$19.9K 2.28% 11
2024
Q2 		$4.47M Buy
23,355
+87
+0.4% +$17.7K 1.93% 12
2024
Q1 		$4.61M Buy
23,268
+895
+4% +$164K 2% 11
2023
Q4 		$3.85M Buy
22,373
+10
+0% +$1.54K 1.82% 17
2023
Q3 		$3.31M Buy
22,363
+270
+1% +$48.8K 1.75% 18
2023
Q2 		$4.83M Buy
22,093
+172
+0.8% +$38.3K 2.47% 7
2023
Q1 		$4.8M Sell
21,921
-84
-0.4% -$18.2K 2.61% 7
2022
Q4 		$4.58M Buy
22,005
+429
+2% +$94.3K 2.67% 6
2022
Q3 		$4.71M Sell
21,576
-17
-0.1% -$3.87K 3.09% 4
2022
Q2 		$4.53M Buy
21,593
+143
+0.7% +$30.4K 2.87% 5
2022
Q1 		$5.2M Sell
21,450
-569
-3% -$138K 2.83% 6
2021
Q4 		$5.74M Buy
22,019
+268
+1% +$69.5K 2.78% 5
2021
Q3 		$5.73M Buy
21,751
+1,176
+6% +$322K 3.14% 4
2021
Q2 		$5.07M Buy
20,575
+1,354
+7% +$285K 2.81% 4
2021
Q1 		$3.73M Buy
19,221
+780
+4% +$156K 2.41% 10
2020
Q4 		$3.92M Buy
18,441
+323
+2% +$64.4K 2.71% 6
2020
Q3 		$3.11M Buy
18,118
+174
+1% +$32.1K 2.42% 10
2020
Q2 		$3.44M Buy
17,944
+711
+4% +$116K 2.93% 4
2020
Q1 		$2.54M Sell
17,233
-754
-4% -$120K 2.64% 8
2019
Q4 		$2.79M Sell
17,987
-85
-0.5% -$12.3K 2.27% 11
2019
Q3 		$2.44M Sell
18,072
-34
-0.2% -$4.46K 2.12% 12
2019
Q2 		$2.21M Sell
18,106
-71
-0.4% -$7.87K 1.92% 15
2019
Q1 		$1.89M Buy
18,177
+145
+0.8% +$15K 1.72% 18
2018
Q4 		$2.05M Buy
+18,032
New +$1.93M 2.14% 12

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eukles Asset Management's RMD Position: Q1 2026 in Review

Eukles Asset Management reduced its ResMed (RMD) stake by 15% in Q1 2026, selling an estimated $828K and leaving 19,413 shares worth $4.36M. The position accounts for 1.94% of the portfolio, ranked #14.

Eukles Asset Management first reported a position in RMD in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.26M in Q3 2025. 939 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Eukles Asset Management held 19,413 shares of ResMed worth $4.36M as of Q1 2026.
  • Eukles Asset Management sold 3,323 ResMed shares in Q1 2026, an estimated $828K.
  • ResMed made up 1.94% of Eukles Asset Management's portfolio in Q1 2026, its #14 holding.
  • Eukles Asset Management first reported a position in ResMed in Q4 2018 and has held it in 30 quarters since.
  • Eukles Asset Management's ResMed position peaked at $6.26M in Q3 2025.
  • 939 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Eukles Asset Management's 13F filing for Q1 2026, filed 5 May 2026.